Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL (BRIDGE-NK)

11 août 2026 mis à jour par: Rong Tao

BRIDGE-NK: A Randomized, Open-Label, Prospective Phase III Study of Immunotherapy Induction Versus Chemotherapy Induction Followed by Autologous Hematopoietic Stem Cell Transplantation Consolidation in Newly Diagnosed Advanced Extranodal NK/T-Cell Lymphoma

This is a randomized, open-label, prospective, multicenter phase III superiority study in patients with newly diagnosed stage IV extranodal NK/T-cell lymphoma. The study compares two frontline induction strategies followed by consolidation with autologous hematopoietic stem cell transplantation in patients who achieve a protocol-defined strict complete remission.

Eligible participants will be randomized 1:1 to Arm A or Arm B, stratified by three-level PINK-E risk category. Arm A consists of one cycle of GELAD induction followed by three cycles of MEDA chemotherapy. Participants who achieve strict complete remission after key response assessment will proceed to autologous hematopoietic stem cell transplantation consolidation. Arm B consists of four cycles of LEAP induction with sintilimab, pegaspargase, and anlotinib. Participants who achieve strict complete remission will receive high-dose methotrexate CNS-directed consolidation followed by autologous hematopoietic stem cell transplantation consolidation if eligible.

The primary endpoint is event-free survival within 24 months after randomization. Secondary endpoints include progression-free survival, overall survival, overall response rate, complete remission rate, strict complete remission rate, autologous hematopoietic stem cell transplantation completion rate, cumulative incidence of relapse, grade 3 or higher adverse events, treatment discontinuation, treatment-related mortality, and plasma EBV-DNA clearance dynamics.

Aperçu de l'étude

Description détaillée

Extranodal NK/T-cell lymphoma is an aggressive Epstein-Barr virus-associated lymphoma with poor outcomes in advanced-stage disease. High-dose methotrexate-containing asparaginase-based chemotherapy can induce responses but is limited by early toxicity, organ dysfunction, infection risk, and incomplete treatment delivery in patients with high tumor burden. PD-1 antibody-based immunotherapy combinations have shown promising activity and tolerability in advanced-stage disease, but randomized evidence comparing immunotherapy induction with chemotherapy induction in a frontline curative-intent strategy remains lacking.

This study is designed to evaluate whether immunotherapy induction followed by CNS-directed high-dose methotrexate consolidation and autologous hematopoietic stem cell transplantation can improve event-free survival compared with a conventional chemotherapy induction strategy followed by autologous hematopoietic stem cell transplantation. The comparison focuses on the entire treatment strategy, including induction depth, feasibility of subsequent consolidation, and early strategy failure, rather than isolated response to a single regimen.

Strict complete remission is defined as all of the following: complete metabolic remission on PET/CT according to Lugano 2014 criteria, negative plasma EBV-DNA, and negative EBER staining on repeat bone marrow biopsy for participants with baseline bone marrow involvement.

Type d'étude

Interventionnel

Inscription (Estimé)

150

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Rong Tao, MD & PhD
  • Numéro de téléphone: 660103 008621-64175590
  • E-mail: hkutao@hotmail.com

Sauvegarde des contacts de l'étude

  • Nom: Chuanxu Liu, MD & PhD
  • Numéro de téléphone: 660103 008621-64175590
  • E-mail: liuchaunxu@shca.or.cn

Lieux d'étude

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 200433
        • Recrutement
        • Fudan University Shanghai Cancer Center,
        • Contact:
          • Rong Tao, MD & PhD
          • Numéro de téléphone: 660103 008621-64175590
          • E-mail: hkutao@hotmail.com
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Age 18 to 70 years at the time of signing informed consent.
  • Histologically confirmed extranodal NK/T-cell lymphoma according to the current classification criteria, with tumor tissue confirmed to be EBER positive. Central pathology review is recommended.
  • Stage IV disease according to Lugano 2014 staging criteria, with baseline staging including PET/CT and bone marrow evaluation.
  • Previously untreated disease, with no prior systemic anti-lymphoma therapy, radiotherapy, or other anti-tumor treatment for NKTCL.
  • At least one evaluable lesion assessable by PET/CT and/or contrast-enhanced CT/MRI.
  • Eastern Cooperative Oncology Group performance status score of 0 to 3.
  • Adequate hematologic function during screening, defined as absolute neutrophil count ≥1.0 × 10^9/L, hemoglobin >80 g/L, and platelet count >50 × 10^9/L.
  • Adequate hepatic and renal function during screening, defined as alanine aminotransferase and aspartate aminotransferase ≤2 × upper limit of normal, total bilirubin ≤2 × upper limit of normal, and creatinine clearance ≥60 mL/min.
  • No severe uncontrolled coagulation disorder, and judged by the investigator to be able to receive pegaspargase-containing therapy.
  • Judged by the investigator to have no absolute contraindication to key components of the assigned treatment strategy, including irreversible contraindication to high-dose methotrexate, severe organ dysfunction precluding transplant evaluation, or other conditions clearly preventing completion of the protocol-defined strategy.
  • Written informed consent provided by the participant or legally authorized representative.

Exclusion Criteria:

  • Prior systemic anti-lymphoma therapy, radiotherapy, or investigational anti-tumor therapy.
  • Active central nervous system lymphoma involvement, including active brain parenchymal, meningeal, cerebrospinal fluid, or intraocular involvement.
  • Active infection requiring intensive care support, or infection judged by the investigator to be uncontrolled and likely to significantly interfere with protocol treatment.
  • Known history of acute or chronic pancreatitis, or any condition judged by the investigator to be an absolute contraindication to pegaspargase.

Fulminant disseminated intravascular coagulation, or severe coagulation disorder judged by the investigator to be uncorrectable in the short term and to substantially increase treatment risk.

  • Severe cardiac, pulmonary, hepatic, renal, or other major organ dysfunction that, in the investigator's judgment, would significantly interfere with protocol treatment.
  • Irreversible contraindication to high-dose methotrexate, including but not limited to marked renal failure, inability to receive standardized hydration, alkalization, leucovorin rescue, or methotrexate clearance monitoring, or any condition judged by the investigator to prevent safe administration of methotrexate within the protocol-defined strategy.
  • Active hepatitis C virus infection, human immunodeficiency virus infection, or active uncontrolled hepatitis B virus replication.
  • Uncontrolled severe hypertension, active bleeding, recent major thromboembolic event, or vascular high-risk condition judged by the investigator to preclude safe administration of anlotinib.
  • Pregnant or breastfeeding women, or participants of reproductive potential unwilling to use effective contraception during the study.
  • Any other medical, psychological, social, or compliance-related condition that, in the investigator's judgment, makes the participant unsuitable for this study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Arm A: Chemotherapy Induction Followed by Autologous HSCT Consolidation
Participants randomized to Arm A will receive one 21-day cycle of GELAD induction followed by three 21-day cycles of MEDA chemotherapy. After completion of GELAD ×1 plus MEDA ×3, participants will undergo key response assessment with PET/CT, plasma EBV-DNA testing, and repeat bone marrow biopsy with EBER staining if bone marrow was involved at baseline. Participants who achieve strict complete remission will proceed to autologous hematopoietic stem cell transplantation consolidation if eligible. Participants who do not achieve strict complete remission and require non-protocol anti-tumor therapy will be managed according to the protocol-defined event rules.
Gemcitabine 1.0 g/m² on day 1, etoposide 60 mg/m² on days 1-3, pegaspargase 2000 IU/m² on day 4, and dexamethasone 40 mg on days 1-4, repeated every 21 days for 1 cycle.
Methotrexate 3.0 g/m² on day 1 as a 3-hour intravenous infusion, etoposide 100 mg/m² on days 2-4, dexamethasone 40 mg on days 1-4, and pegaspargase 2500 IU/m² on day 4, repeated every 21 days for 3 cycles.
Participants achieving strict complete remission will undergo autologous hematopoietic stem cell transplantation according to institutional transplant procedures if eligible.
Expérimental: Arm B: Immunotherapy Induction Followed by HD-MTX and Autologous HSCT Consolidation
Participants randomized to Arm B will receive four 21-day cycles of LEAP induction with sintilimab, pegaspargase, and anlotinib. After completion of LEAP ×4, participants will undergo key response assessment with PET/CT, plasma EBV-DNA testing, and repeat bone marrow biopsy with EBER staining if bone marrow was involved at baseline. Participants who achieve strict complete remission will receive high-dose methotrexate CNS-directed consolidation for up to 3 doses, followed by autologous hematopoietic stem cell transplantation consolidation if eligible.
Participants achieving strict complete remission will undergo autologous hematopoietic stem cell transplantation according to institutional transplant procedures if eligible.
Sintilimab 200 mg intravenously on day 1, pegaspargase 2500 IU/m² on day 1 with a maximum single dose of 3750 IU, and anlotinib 8 mg orally on days 1-14, repeated every 21 days for 4 cycles.
Participants who achieve strict complete remission after LEAP induction will receive methotrexate 3.0 g/m² as a 3-hour intravenous infusion every 2 weeks for up to 3 doses, with hydration, urine alkalization, leucovorin rescue, and methotrexate concentration monitoring.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Event-Free Survival Within 24 Months
Délai: From randomization to the first protocol-defined EFS event or administrative censoring at 24 months after randomization
Event-free survival is defined as the time from the date of randomization to the first occurrence of any of the following events: disease progression; death from any cause; inability to complete the assigned protocol-defined treatment strategy due to severe adverse events, persistent organ toxicity, treatment-related complications, or other unacceptable toxicity; or failure to achieve strict complete remission at the key response assessment followed by initiation of non-protocol anti-tumor therapy. Participants without an EFS event at 24 months after randomization will be administratively censored at 24 months.
From randomization to the first protocol-defined EFS event or administrative censoring at 24 months after randomization

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Progression-Free Survival
Délai: From randomization to disease progression, relapse, death, or last disease assessment, assessed up to 66 months
Progression-free survival is defined as the time from randomization to documented disease progression, relapse after response, or death from any cause, whichever occurs first. Participants without an event will be censored at the date of the last valid disease assessment.
From randomization to disease progression, relapse, death, or last disease assessment, assessed up to 66 months
Overall Survival
Délai: From randomization to death or last confirmed survival status, assessed up to 66 months
Overall survival is defined as the time from randomization to death from any cause. Participants who are alive will be censored at the last date they are known to be alive.
From randomization to death or last confirmed survival status, assessed up to 66 months
Percentage of Participants With at Least One Serious Adverse Event
Délai: From the first dose of protocol treatment through 30 days after the last protocol treatment, and through Day +90 after autologous HSCT for transplanted participants, assessed up to 12 months.
The percentage of participants who experience at least one serious adverse event, as defined in the study protocol, during the specified assessment period. Each participant will be counted once regardless of the number of serious adverse events experienced. Serious adverse events will be assessed by the investigator for relationship to protocol treatment.
From the first dose of protocol treatment through 30 days after the last protocol treatment, and through Day +90 after autologous HSCT for transplanted participants, assessed up to 12 months.
Percentage of Participants With at Least One Grade 3 or Higher Adverse Event
Délai: From first dose of protocol treatment through 30 days after the last protocol treatment, and through Day +90 after autologous HSCT for transplanted participants, assessed up to 12 months
The percentage of participants who experience at least one grade 3 or higher adverse event, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Each participant will be counted once according to the highest adverse event grade experienced during the assessment period.
From first dose of protocol treatment through 30 days after the last protocol treatment, and through Day +90 after autologous HSCT for transplanted participants, assessed up to 12 months
Percentage of Participants Who Permanently Discontinue a Key Component of the Assigned Treatment Strategy Due to Adverse Events
Délai: From first dose to permanent discontinuation of assigned protocol treatment, assessed up to 12 months
The percentage of participants who permanently discontinue at least one key component of the assigned protocol-defined treatment strategy because of an adverse event, treatment-related toxicity, or treatment-related complication. Each participant will be counted once.
From first dose to permanent discontinuation of assigned protocol treatment, assessed up to 12 months
Strict Complete Remission Rate at Key Response Assessment
Délai: At key response assessment after assigned induction treatment, approximately 12-20 weeks after randomization
Strict complete remission rate is defined as the proportion of participants who meet all of the following criteria: complete metabolic remission on PET/CT, negative plasma EBV-DNA, and negative EBER staining on repeat bone marrow biopsy among participants with baseline bone marrow involvement.
At key response assessment after assigned induction treatment, approximately 12-20 weeks after randomization
Percentage of Participants With Treatment-Related Mortality
Délai: From first dose through 30 days after the last protocol treatment, and through Day +90 after autologous HSCT for transplanted participants, assessed up to 12 months
The percentage of participants who die from an adverse event or complication judged by the investigator to be related to protocol treatment, treatment-related supportive procedures, or autologous hematopoietic stem cell transplantation.
From first dose through 30 days after the last protocol treatment, and through Day +90 after autologous HSCT for transplanted participants, assessed up to 12 months
Percentage of Baseline Plasma EBV-DNA-Positive Participants With Plasma EBV-DNA Clearance at the Key Response Assessment
Délai: At the key response assessment after completion of assigned induction treatment, approximately 12 to 20 weeks after randomization.
The percentage of participants with detectable plasma Epstein-Barr virus DNA at baseline who achieve plasma EBV-DNA clearance at the key response assessment. Plasma EBV-DNA will be measured using quantitative real-time polymerase chain reaction and reported in copies/mL. Plasma EBV-DNA clearance is defined as a decrease from a detectable baseline value to less than 500 copies/mL or below the lower limit of quantification of the assay. The denominator will include baseline plasma EBV-DNA-positive participants with an evaluable plasma EBV-DNA result at the key response assessment.
At the key response assessment after completion of assigned induction treatment, approximately 12 to 20 weeks after randomization.
Overall Response Rate at Key Response Assessment
Délai: At key response assessment after assigned induction treatment, approximately 12-20 weeks after randomization
Overall response rate is defined as the proportion of participants achieving complete remission or partial remission according to Lugano 2014 criteria at the key response assessment.
At key response assessment after assigned induction treatment, approximately 12-20 weeks after randomization
Percentage of Randomized Participants Who Complete Autologous Hematopoietic Stem Cell Transplantation
Délai: From randomization to completion of autologous HSCT, assessed up to 12 months
The percentage of all randomized participants who complete autologous hematopoietic stem cell transplantation after achieving protocol-defined strict complete remission and meeting transplant eligibility criteria. The denominator will include all randomized participants in each treatment arm.
From randomization to completion of autologous HSCT, assessed up to 12 months
Cumulative Incidence of Relapse Among Participants Who Achieve Strict Complete Remission
Délai: From the date of first documented strict complete remission to relapse, death, or the last valid disease assessment, assessed up to 66 months after randomization.
The cumulative incidence, expressed as a percentage, of first lymphoma relapse among participants who achieve protocol-defined strict complete remission at the key response assessment. Relapse will be assessed according to Lugano 2014 criteria using PET/CT and, where clinically indicated, contrast-enhanced CT or MRI, bone marrow evaluation, and plasma EBV-DNA testing. Death without documented relapse will be treated as a competing event.
From the date of first documented strict complete remission to relapse, death, or the last valid disease assessment, assessed up to 66 months after randomization.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chaise d'étude: Rong Tao, MD & PhD, Shanghai Cancer Center
  • Chercheur principal: Chuanxu Liu, MD & PhD, Shanghai Cancer Center

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

11 août 2026

Achèvement primaire (Estimé)

31 décembre 2031

Achèvement de l'étude (Estimé)

31 décembre 2031

Dates d'inscription aux études

Première soumission

16 juin 2026

Première soumission répondant aux critères de contrôle qualité

24 juin 2026

Première publication (Réel)

1 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 août 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Description du régime IPD

IPD sharing is currently undecided. The study team will determine whether de-identified participant-level data can be shared after study completion in accordance with institutional policy, participant consent, and applicable regulations.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner